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R&D Project Valuation and Licensing 
Negotiations at Phytopharm plc 
 
Abstract 
We describe an R&D project valuation model developed for Phytopharm plc, an emerging 
pharmaceutical company based in Cambridge, UK.  The model allows the company to value the 
projects in its R&D portfolio, and is used for licensing negotiations with potential product 
development and marketing partners.  It is based on different valuation methods, including Net 
Present Value, Decision Analysis and Monte Carlo Simulation.  We take into account the 
technological risks during the development phases of pharmaceutical products, as well as the 
uncertainty in terms of commercial success.  In addition to determining a value for a product in 
development, the model also proposes appropriate contract structures for licensing purposes.  A 
typical pharmaceutical licensing contract specifies milestone payments and royalties, to be paid by the 
licensee to the licensor.  The contract structures adhere to an agreed-upon equitable split of the project 
value between the two parties.  The model also generates critical information during the negotiation 
meetings in terms of break-even analyses, trade-offs and bargaining zones.  It was used by 
Phytopharm during 2004 in its licensing negotiations for a novel product for the dietary control of 
obesity, which was licensed in December 2004 to Unilever, a multinational food company.  
Phytopharm is currently deploying the model for its entire project portfolio. 
 
Keywords 
Project Valuation, Negotiation, Pharmaceuticals, Decision Analysis, Monte Carlo Simulation, Real 
Options 
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Introduction 
The structure of the pharmaceutical industry is changing as many large pharmaceutical companies 
struggle to fill their product pipeline.  Rather than relying on in-house research projects, these 
companies rely more and more on small biotechnology companies to provide innovation and novel 
therapeutic approaches, resulting in an increase in the number of licensing deals.  This allows the 
major pharmaceutical companies to focus on their core strengths such as manufacturing, distribution, 
marketing and sales.  For instance, in 2002, Merck reviewed thousands of licensing opportunities, and 
completed on 32 deals (Drug Week, 2003).  Meanwhile, several factors have contributed to the rise in 
the cost of pharmaceutical development beyond the capabilities of most smaller companies, including 
(a) tighter regulation, which has led to increasing development costs, (b) dedicated and sophisticated 
production facilities required by the new generation of biochemical pharmaceuticals, and (c) huge 
marketing efforts necessary for a successful world-wide launch of new products. This evolution has 
prompted smaller companies to turn to the major players in the industry and to offer licensing 
opportunities.  
Phytopharm plc is an emerging pharmaceutical company, based in Cambridge, UK and listed on 
the London Stock Exchange, established in 1990 and floated in 1996.  The company specializes in the 
discovery and development of plant-based medicines, examining plants with an anecdotal history of 
clinical benefit (Figure 1).  Phytopharm is working in four disease areas, namely the 
neurodegeneration area targeting Alzheimer’s, Parkinson’s and motor neuron diseases, the metabolic 
disease area focusing on obesity and metabolic diseases, dermatology and inflammation.  Phytopharm 
actively tries to reduce its risk exposure by out-licensing its products in development, and seeking 
early commercialization of secondary products, such as food and veterinary products.  Phytopharm’s 
extensive recourse to outsourcing of the laboratory work and clinical testing to specialists, and the 
systematic licensing of its projects once proof of principle is passed, allows it to maintain a strong 
focus on its core competencies, namely pre-clinical and clinical strategy and management. 
 
 
Figure 1.  Phytopharm’s R&D strategy compared to the classic pharmaceutical route to market. 
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Phytopharm typically performs the first steps of pharmaceutical research: isolating the active 
compound, identifying the mode of action, and taking the novel compounds through the 
pharmaceutical development process until the successful completion of proof of principle, i.e. the pre-
clinical and toxicology phase and Phase I and II clinical trials. If proof of principle is achieved, 
Phytopharm licenses the project out to large pharmaceutical partners that have the financial, R&D and 
marketing resources to further develop and launch the product. Phytopharm’s revenues consist 
entirely from licensing agreements for their projects.  A licensing deal typically contains a 
downpayment at contract signature, lump sum payments on successful completion of specific 
milestones and royalties on sales.  The strategic emphasis on risk reduction means that Phytopharm 
has a preference for downpayments and milestone payments. 
When Phytopharm’s management team contacted us in October 2003, they were preparing to start 
negotiations for the Hoodia gordonii extract, a new product for the dietary control of obesity.  
Phytopharm had acquired the exclusive license to develop and market a natural appetite suppressant 
derived from the Hoodia gordonii succulent, which grows in the African Kalahari desert.  Hoodia 
species have been used by the Xhomani San people for centuries as a food of last resort to stave off 
hunger and thirst.  Examining this plant, the South African Council for Scientific and Industrial 
Research discovered the appetite suppressant properties of Hoodia gordonii extract and recognized 
the extract’s potential as an anti-obesity agent.  The patented extract was licensed to Phytopharm in 
1997, who developed a pharmaceutical product based on Hoodia gordonii extract that successfully 
achieved proof of principle in clinical trials of healthy overweight men in 2001.1 
 
Figure 2. Hoodia gordonii cultivated by Phytopharm for the DCO product. 
                                                           
1 Interfaces, INFORMS and the authors have no opinion on the scientific case for or against Hoodia Gordonii, 
nor have the claims of Phytopharm regarding the effectiveness of Hoodia Gordonii been reviewed for the 
purpose of this article, which only describes the use of decision tools in aiding R&D licensing negotiations. 
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To enhance revenues and reduce risk, Phytopharm pursued a differentiation strategy, pitching the 
product at two different markets.  On the one hand, research was conducted to manufacture the plant 
derived active compound synthetically.  Though this is a complex and expensive process, it allows 
cheap bulk production and targeted improvement of the molecule, making it ideal for the 
pharmaceutical industry as a prescription drug.  On the other hand, Phytopharm was developing a 
botanical product for use as a food additive.  Both applications were covered by patents.  The natural 
compound is covered until 2018, though a new filing has been made that should extend protection 
until 2025.  In May 2004, Phytopharm was preparing to start negotiations for the botanical product 
with multinational food companies. Even though management was confident that this could be a 
blockbuster product, i.e. with annual sales over US$1 billion, Phytopharm needed to have a 
comprehensive and flexible methodology to predict and value the product’s potential in a rigorous 
way.  Also, Phytopharm wanted a model to support the licensing negotiations for their products – the 
determination of upfront payments, milestone payments and royalties – and enable it to appraise the 
value of its projects, to improve shareholder value and portfolio management. 
This paper presents the model we have developed for Phytopharm.  Throughout the text we 
combine the description of the model with an account of our relations with Phytopharm and the 
model’s impact on project valuation and negotiation.  The first section provides background 
information on the pharmaceutical development process, and highlights the consequences for this 
particular DCO product.  The second section provides details on the valuation model.  The third 
section briefly describes the sensitivity and simulation functionalities included in the model and the 
fourth section presents the tools designed to support Phytopharm in their negotiations.  Before 
concluding, we report on Phytopharm’s use of the model, internally and externally. 
A study for a similar product is presented in Ruback and Krieger (2000), where a decision analysis 
model is proposed to value a licensing opportunity, using the given project parameters.  We add to 
this by performing the complete model cycle: problem definition, data collection, model design, 
project valuation, sensitivity analysis, negotiations support and implementation of the model in 
practice.  Other papers present a real options approach to project valuation (Hearth and Park, 1999; 
Lewis, Enke and Spurlock, 2004).  However, these papers mainly present theoretical developments 
and may not be directly accessible to practitioners as they do not provide details on how to develop 
such a model and on the impact of the application of the valuation methodology.  For a 
comprehensive review on optimal models for licensing, we refer to Crama, De Reyck and Degraeve 
(2005). 
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The Pharmaceutical Development Process 
Pharmaceutical development is a risky, time-consuming and expensive process.  The average time 
from compound to market has grown from 8.1 years in the 1960s, to 11.6 years in the 1970s, to 14.2 
years in the 1980s and 1990s (DiMasi, 2001).  Lengthening development times also increase 
development costs; recent estimates indicate that the cost of developing a medicine is around $900 
million (DiMasi et al., 2003), which includes expenditures on failed products.  Newly developed 
medicines are protected by patents, typically for 20 years, although in practice this results in a post-
regulatory approval patent life of approximately 12 years. 
The pharmaceutical registration process is heavily regulated.  Stringent scientific procedures have 
to be followed to ensure patient safety in distinct stages, including pre-clinical and clinical tests, 
before a medicine can be approved for production and marketing.  The pharmaceutical development 
process in the United States is monitored by the U.S. Food and Drug Administration (FDA).  
Comparable institutions exist in other countries around the world, like the European Agency for the 
Evaluation of Medicinal Products (EMEA), which grants marketing authorization for the EU.  The 
pharmaceutical development and review process is typically as given in Table 1.  
 
Phase Typical 
duration 
Probability of advancing
to next stage 
Probability 
of FDA approval 
Proportion of total R&D costs 
(including failed products) 
Basic Research 2 years 0.4% 0.02% 24% 
Pre-Clinical 3 years 25% 5% 12% 
Clinical I, II, III 6 years 25% 20% 29% 
FDA Review 1-2 years 80% 80% 35% 
Table 1. The typical pharmaceutical development and review process takes a substantial 
number of years and carries a high risk of failure. 
On average, only one in five medicines entering clinical trials is launched, and only one in five 
thousand compounds in the research phase makes it to the market.  As a consequence, a large portion 
of all development costs is spent on medicines that never reach the market, illustrating the high 
technical risks involved.  In addition, of those medicines that are commercialized, only 30% achieve 
the commercial success necessary to recover the (after-tax) development costs to yield a healthy 
return, illustrating the additional commercial risks involved (Grabowski et al., 1994).  Nevertheless, 
pharmaceutical companies in recent years have been able to report healthy profits, of about 20% on 
gross revenues. 
Phytopharm hoped the FDA would grant the functional food product “GRAS” (generally 
recognized as safe) status, which was thought to be a way of achieving robust label claims.  
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Phytopharm’s strategic focus on plant derived products with anecdotal evidence of clinical benefit 
produces novel products with potentially lower development risk in terms of both efficacy and safety. 
Since the pharmaceutical grade botanical extract had shown statistically significant reductions in 
calorie intake in early clinical trials, marketing a food grade botanical extract as a functional food in 
combination with nutrients and calories seemed to be the most natural method of delivering the 
product to consumers in an effective but safe way.  As a result, Phytopharm was negotiating with food 
companies as potential licensees, and it was feared that they would not be familiar with the particular 
product development processes, and that this might create some problems during the negotiations. 
 
The Valuation Model 
General features 
We have developed a model that allows valuing the projects in Phytopharm’s portfolio using Net 
Present Value, Decision Analysis and Monte Carlo simulation.  The model also enables the valuation 
of different licensing contracts and payment structures based on milestone payments and sales 
royalties, by computing the Net Present Value provided by the contract for Phytopharm and the 
potential licensee, and analyzing how the risk is shared between the two parties.  The model assists 
Phytopharm’s management in its negotiations when discussing licensing deals for its products in 
development. 
Phytopharm contacted us after a consulting agency delivered a valuation model that worked as a 
black box, with which they did not feel comfortable.  Therefore, our model was built with three main 
features in mind: transparency, parameterization and flexibility.  First, Phytopharm requested a 
transparent model and wanted to avoid the black-box phenomenon often associated with externally 
developed models.  This is particularly relevant in this context where Phytopharm management 
wanted to present the model to licensing partners, and to make it a credible basis for negotiation.  
Second, extensive use of parameterization in the model was essential, allowing the negotiation 
partners to discuss the assumptions underlying the valuation model, and to change the settings during 
the negotiations, with immediate effect on the valuation results.  In an effort to improve 
understanding, many of these parameters required an intuitive graphical representation in the model.  
Finally, as Phytopharm conducts negotiations for several different projects, management wanted a 
model that would be sufficiently generic and flexible and that could be used for different projects. 
The valuation model is built in Excel using Visual Basic for Applications (VBA), with a separate 
add-in for Risk Analysis and Monte Carlo Simulation.  We used @Risk for Excel, developed by 
Palisade Corporation (www.palisade.com).  The layout of the spreadsheets in the model was carefully 
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designed according to the principles of good spreadsheet design (Powell and Baker, 2004), 
contributing considerably to an enhanced transparency of the model. 
Development Stage Model 
We will describe how the model was used to value the ‘dietary control of obesity’ project, or DCO 
project, in Phytopharm’s portfolio.  Although the DCO product will be a functional food product, its 
development follows the same project structure as a typical pharmaceutical product.  Phytopharm had 
already achieved proof of principle for the original botanical pharmaceutical product after 
successfully completing the pre-clinical and clinical phases I and II, but was seeking to attract a 
licensing partner to develop and market the DCO product.  The project is composed of two distinct 
parts: (a) the R&D stage, consisting of a basic research stage and a development stage including pre-
clinical and clinical trials, manufacturing and pre-launch marketing, and (b) the market stage, 
following the market introduction.   
The R&D stage was fully documented by Phytopharm who submitted a detailed project plan to its 
negotiation partners.  A part of the project plan is shown in Figure 3.2  The cost and timing parameter 
estimates in the model are derived from this plan, and can be changed in real time during the 
negotiations, to examine their impact on the project value.  The project stages are also derived from 
the project plan, and are agreed upon by both parties.  Theoretically, it should be in the interest of 
both parties to identify as many milestones as possible, as this increases the number of abandonment 
options included in the project.  However, during the negotiations, we noticed a diverging agenda for 
both parties.  Phytopharm typically prefers to keep the number of stages small because that seems to 
increase the negotiation partner’s estimate of the project’s overall probability of technical success 
(PTS).  The reason for this is that very often, the negotiation partner does not have an overall PTS in 
mind that is allocated to the different project phases, but assigns a certain probability per phase that 
then combines into the overall PTS.  This second approach tends to yield a lower overall PTS when 
the number of phases is high.  Thus, both the number of stages and the PTS of each stage are an 
integral part of the negotiation process and are based on estimates by experts at Phytopharm, using 
historical data adapted for the specificities of the project under evaluation. 
The R&D stage consists of a series of development phases, and for each phase the model captures 
the development cost, probability of success and start and end dates.  Initial marketing costs incurred 
before launch are also attributed to the appropriate phase.  In the model, the project is represented as a 
decision tree, in which a new phase will only be started if the previous phase was successful, and the 
project will only be successful if all its phases are successful. 
                                                           
2 All the data reported in this paper concerning the DCO project is disguised. 
 Figure 3.  The DCO project plan contains details on the timing and cost of each of the project phases and activities (disguised data). 
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Since the number of stages was an outcome of initial discussions, it was important to make it 
flexible in the model and allow Phytopharm to change it interactively.  To facilitate this, we included 
in the model a graphical representation of the resulting decision tree (Figure 4).  Note that in this 
project, failure automatically forces the termination of the entire project, whereas success implies 
continuation.  Decision nodes could be added to model additional options. 
The launch date for this project is set for early 2007.  Given the limited patent life, a delay in the 
product launch can be very costly in terms of lost sales.  Conversely, it is interesting to note that even 
though reducing the project duration may be an attractive proposition, yielding longer monopoly 
profits, working with natural compounds makes it more difficult to do so as a minimum time is 
required for the plants to grow to maturity.   
 
Figure 4.  A decision tree is used to present the project structure, and includes information regarding 
timing, cost and probabilities of technical success for each of the project phases.  The decision tree is 
drawn automatically at the push of a button (disguised data). 
Market Stage Model 
The DCO product in its food product version is designed to target the meal replacement and 
nutritionals market, which includes calorie-controlled meals, bars, powders and beverages.  The 
product would be launched first in the US, the world’s largest healthcare market.  In 2003, the US 
meal replacement market reached a total value of approximately $1.5 billion, with steady double-digit 
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growth rates over the past several years.  Phytopharm provided us with their own sales estimates, 
based on the population of obese, overweight and diabetics.  However, their standard valuation 
approach would be difficult to defend in negotiations. 
In order to derive credible estimates of future demand, we developed a model that was consistent 
with the custom in the pharmaceutical industry, where standard growth curves are typically used to 
generate sales forecasts, with S-curves being the most prevalent type.  The advantage of these curves 
is the flexibility that they offer to generate different growth patterns and product life cycles.  Initially, 
we considered a Bass curve (Bass, 1969), which models the diffusion of a new product in a market 
and is widely used in practice.  However, that model does not look at the individual brand level, and 
thus does not acknowledge the impact of competitor entry on branded product sales.  As long as the 
product is protected by patents, this is a fair representation of reality.  However, as soon as 
competitors enter the market, they may take over a substantial share of the market.  Therefore, we 
developed a sales forecasting model based on the number of people purchasing meal replacement 
products, using a modified version of the trial-repeat model of Lilien, Rao and Kalish (1981), which 
explicitly allows for switching between brands. The model estimates the evolution in sales by 
modeling the number of potential clients trying out the product, then becoming repeat purchasers and 
finally switching brands, holding the average expenditure on the product constant. It can be expressed 
as follows: 
( )
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where tx are the new adopters in period t, tX  the cumulative number of users in period t  and X  the 
size of the target market of the product.  The parameter te  represents the marketing effort with 
decreasing marginal returns ( 02 <y ), te  is the marketing effort for competing products and ( )txw  is 
the word-of-mouth effect, a linear function of the number of new adopters.  The parameter te  is zero 
before competitor’s entry, and is strictly positive thereafter, which allows to model a sudden drop in 
sales at the time of patent expiry.  Sales ts  are computed by multiplying the total number of users by 
the average expenditure f  per user.  The parameters shaping the sales growth curve are 1y , 2y , 3y , 
X  and the year in which competitors enter the market.  Using these five parameters, several different 
shapes for the sales growth curve can be obtained, ranging from standard S-shapes to shapes including 
a drop in sales after patent expiry. 
Additionally, we have extended the model to include capacity constraints.  Such constraints are 
highly relevant for organically-grown products, such as the DCO product, that require an agronomy 
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phase during which the product is farmed and harvested, and for which production capacity can only 
be gradually created.  Therefore, there is a distinct possibility that Phytopharm will not be able to fully 
meet demand for the product in the early years.  The model allows specifying a limit tz  on the 
number of people who can be served each year.  A binding capacity constraint results in reduced sales 
in the year in which capacity is reached, but also has an indirect effect on sales in subsequent periods 
since fewer people try out the product, reducing the word-of-mouth effect. 
We have made initial estimates of these parameters based on data retrieved from market research 
reports, which estimate the market potential for meal replacement products as approximately 15 
million people, spending on average $140 per year on slimming products (MarketData Enterprises, 
2002).  Once more, the market data parameters can be changed during the negotiation, and can be 
driven by the potentially superior market knowledge of the negotiation partner.  We therefore decided 
to build the model so as to allow that flexibility in an intuitive way with immediate graphical 
representation of the consequences of each parameter on the sales estimate.  In the sensitivity analysis, 
we also allow for uncertainty on these estimates in the form of ranges.  An additional reason to keep 
the sales model as general as possible was that Phytopharm typically negotiates with several parties in 
very different industries.  Patent expiry is a major issue in the pharmaceutical industry, but not 
necessarily in the food industry – and in both cases, brand name building can mitigate the effects on 
sales.  Even within the same industry, different companies operate under different market situations.  
Unilever, for example, already owns a range of slimming products, and does not face the same 
challenges at product introduction since it can incorporate the compound into its existing brand and 
thus bypass the slow adoption process.  
Our model allows sales forecasts up to a horizon of 25 years, with a terminal value capturing the 
present value of a perpetuity based on sales in year 25.  Based on our discussions with the CEO and 
CFO, as well as the marketing manager, we have opted for a slightly longer time horizon than the 
patent life because many pharmaceutical companies actively engage in brand name recognition in 
order to prevent the drastic sales decline that the loss of patent protection often entails. 
Figure 5 shows the “Sales” sheet for the DCO product, which contains information on sales 
forecasts and related expenditures.  The following information needs to be entered (cell references 
between brackets): launch date (D2); the market size or target population, in this case, the number of 
people buying meal replacement products (D4); peak market penetration rate as a percentage of the 
total target population (D5); market growth (D6); the percentage of initial adopters (D7); the average 
spend per customer (D8); and the date of competitor entry or patent expiry (D11).  The first scrollbar 
(D9) allows to specify the take-up speed after launch.  In our sales model, this corresponds to the pair 
of values ( 1y , 2y ).  The second scrollbar (D12) determines the sales decay after competitor entry, 
which depends on the impact of competitor’s advertising, 3y .  These scrollbars allow a wide variety 
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of sales growth curve shapes to be modeled.  The curve displayed on the sheet in Figure 4 changes 
automatically when parameter values are changed, allowing the user to visually assess the impact of 
parameters settings on the sales curve. This reduces the difficulty of setting parameters and allows to 
mould a sales curve that fits the expectations of both negotiating parties.   The time to reach peak 
sales is automatically computed (D10).  Finally, information is required on the available capacity in 
each year (row 14), as well as on the required annual marketing expenditures (row 15).  The resulting 
sales estimates are reported in the bottom row of the sheet (row 19). 
 
Figure 5.  The “Sales” sheet allows specifying a sales growth curve (disguised data). 
 
Project Valuation 
Based on the project structure and sales forecasts, the Net Present Value (NPV) of the project can be 
computed using standard NPV calculations.  The project’s discount rate can be set equal to the 
company’s Weighted Average Cost of Capital (WACC), or to any value agreed upon between the two 
parties.  The structural elements of a contract between Phytopharm and a potential licensee are the 
milestone payments, to be paid after the successful completion of each project phase, and royalties, as 
a percentage of sales. When these payments are agreed upon, the NPV of the project is effectively 
divided between the two parties.  Taking the contract terms into account, we can compute the 
licensor’s and the licensee’s NPV. 
The core of the model is the “Valuation Model” sheet, which contains summary information on the 
project’s financials, its value and the value of the deal for Phytopharm and the licensee.  The sheet is 
designed according to the principles of good spreadsheet design (Powell and Baker, 2004), and 
consists of three main sections, labeled “Data”, “Results” and “Model”.  Figure 6 shows the “Data” 
section for the DCO project.  It contains information on the required currency (C2), the anticipated 
launch date (C3), the operating margin (C4) and depreciation as a percentage of gross sales (C5), the 
tax rate for the licensee (C6) and Phytopharm (C7), the agreed-upon royalty as a percentage of gross 
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sales (C8), a provision for intellectual property (IP) rights to be paid by Phytopharm to a third party as 
a percentage on royalties (C9), the risk-free (long-term) discount rate (C10), a discount rate 
appropriate for the project, agreed by both parties (C11), or alternatively, the model automatically 
computes a discount rate for the project (C12), the licensee (C13) and Phytopharm (C14) based on the 
inherent risk in the project and the risk borne by each party. 
The sheet also allows the input per project phase of the start date (row 16), the probability of 
success (row 17), an agreed-upon milestone payment at the start of each phase (row 18), IP rights to 
be paid by Phytopharm to a third party as a percentage of the milestone payment received (row 19), an 
estimate of the development cost (row 20) and pre-launch marketing expenditures (row 21), and an 
error indication showing a message if any of the inputs are missing or incorrect (row 22). 
 
Figure 6.  The DATA sheet contains information on the development stage of the project. 
The “Results” section in Figure 7 contains summary information on the value of the project, and 
how the value is split between the two parties, Phytopharm and the licensee.  The NPV for the project 
is reported (C26), with a breakdown for sales, operating profit, marketing expenditures and 
development costs.  Additionally, based on the milestone payments and royalty percentage in the 
“Data” section, the NPV for Phytopharm (C32) and the licensee (C36) are given, with a breakdown, 
for Phytopharm, in milestone and royalties.  For the licensee, an internal rate of return (C37) and 
payback period (C38) are also provided.  The model also suggests a milestone payment based on the 
probability of technical success of each phase (row 41, more information below), along with an 
indication of the proposed milestone payment as a percentage of the suggested value (row 42). 
The “Model” section in Figure 8 contains a profit and loss statement with annualized information 
on sales (row 50), cost of goods sold (row 51), marketing expenditures (row 52), development costs 
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(row 53), free cash flows (row 54) and an NPV value (C57).  A terminal value (C56) is used to 
capture the revenues beyond the model horizon, i.e. more than 25 years after launch.  For both parties, 
additional information on milestone payments (rows 65 and 75), royalties (row 76), IP rights (row 77) 
and depreciation (row 64) is also included, resulting in profits before and after taxes. 
 
Figure 7.  The RESULTS sheet contains information on the value of the project for both parties. 
 
Figure 8.  The MODEL sheet contains a profit and loss statement for the project and both parties. 
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A discount rate reflecting inherent project risk 
A difficult issue when valuing an R&D project is determining the correct discount rate to be used.  As 
stated above, companies generally use a company-wide WACC, although this may not be appropriate 
if (the risk of) the project being valued is not typical for the projects in the company.  Moreover, the 
discount rate is an important issue in R&D licensing negotiations, because of its high impact on the 
project’s value.  Phytopharm needed an objective approach for determining a discount rate that could 
be used during its negotiations with potential licensing partners as an anchor point for discussion, in 
order to counter the licensee’s inclination to propose an excessively high discount rate. 
Ideally, one should use a discount rate that reflects the systematic, i.e. non-diversifiable, risk of the 
project being valued.  This risk will depend on the risk profile of the project, in terms of variances in 
the project’s returns, on the correlations of those returns with the market returns and on the options 
embedded in the project.  In our valuation model, we use a framework for valuing projects based on 
explicitly determining the correlation of the project’s returns with the market returns.  Our 
methodology is detailed in De Reyck, Degraeve and Vandenborre (2003).  When this correlation is 
known, the present value of the project can be readily determined using the Capital Asset Pricing 
model (Sharpe, 1965; Lintner, 1965).  
Milestone payments based on phase risk 
The model is primarily designed for evaluating licensing deals by examining the value of the 
project and the value of a specified package consisting of milestone payments and royalties.  
However, Phytopharm’s management was also interested in guidelines on the milestone payments, i.e. 
indications of which size of milestone payments would be “appropriate”.  One can think of milestone 
payments as a remuneration for the value created during the preceding phase.  If a phase with a low 
likelihood of technical success is passed successfully, the NPV of the project will increase 
substantially from then onwards.  The milestone payments can be set to reflect this increase.  
Therefore, we adopted the following approach for providing guidelines on suitable milestone 
payments.  At each milestone, i.e. after each phase, we compute the increase in the project’s NPV as a 
result of successfully passing that phase.  A suggested milestone payment is then computed, based on 
the total value of the milestone package, but allocated according to the value created during each 
phase (row 41 in Figure 7).  In effect, this means that the suggested milestone payment depends on the 
probability of technical success of each phase.  The lower the probability, the higher the milestone 
payment if the phase is passed successfully.  Each proposed milestone payment is then expressed as a 
percentage of that increase (row 42 in Figure 7).  This allows Phytopharm and the licensee to agree 
upon an appropriate split of the value creation, which results in suggested milestone payments being 
automatically computed. 
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Sensitivity and Simulation Analysis 
The project’s NPV determined above depends on a number of assumptions, including estimated 
development costs, probabilities of technical success of each project phase, profit margin, launch date, 
patent expiry, phase durations, and sales forecasts, which in turn depend on the market size, the 
penetration rate or market share, and the average spend per customer.  As we have seen throughout 
the discussion of the model, the values for these parameters are reached by agreement between the 
negotiation partners, and are based on expert estimates.  This agreement forms the initial stage of the 
negotiations, on the basis of which the contract terms are discussed.  We included a scenario analysis 
that allowed Phytopharm to explore which parameters had the strongest impact on the project value, 
in order to decide on which parameters to hold strong and on which to possibly compromise during 
the negotiations. 
As shown in Figure 9, for each parameter in the model, an optimistic and pessimistic value can be 
entered, next to the base case or most likely value.  Using the Data Table functionality in Excel, we 
then create tables showing how different parameter settings would affect the NPV values.  A Tornado 
chart is created, listing the ten most influential parameters in order of impact on the project NPV.  An 
example, with disguised information, is shown in Figure 10 for the DCO project. 
 
Figure 9. The scenario sheet specifies optimistic and pessimistic values for each of the model’s 
assumptions, enabling a sensitivity analysis of each model parameter. 
An essential characteristic of R&D projects is a high degree of uncertainty.  In a typical 
pharmaceutical project, it is highly likely that the product does not make it through all the 
development phases.  This technological risk depends on how innovative the product is and how 
unfamiliar the technology.  There is also the risk that the product, when launched, is not commercially 
successful.  This commercial risk depends on general economic conditions, market size, market share, 
profit margin and various other factors. 
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Figure 10. A tornado diagram shows the most influential model parameters, sorted according to their 
impact on the project NPV as their value is varied between its optimistic and pessimistic estimate. 
We have included functionalities in our model that allows a Monte Carlo simulation analysis to 
investigate the technological and commercial risk of an R&D project.  The simulation provides an 
extended sensitivity analysis and a graphical representation of the risk sharing resulting from the 
contract terms.  The simulation results are based on the probabilities of technical success of each of 
the project phases, and on the ranges on each of the model’s parameters specified in the sensitivity 
analysis section.  For the development stage, we use binomial distributions using the probability of 
technical success of each phase, whereas for the market stage, we use triangular distributions for each 
parameter, with the mode equal to the specified base case value, and the tail percentiles equal to the 
specified pessimistic and optimistic values.  By taking random samples from the distributions for each 
parameter, we obtain the possible range of values for the NPV of the project, allowing us to construct 
a confidence interval.  This can be done for the project as a unit of analysis, or separately for 
Phytopharm’s contract and for the licensee’s contract. 
Simulation results are provided in the model in the form of histograms and cumulative probability 
distributions for the project’s NPV and the NPV for both parties.  Figures 11 and 12 show these 
graphs for the DCO project, obtained using the Excel add-in @Risk.  Brealey and Myers (2000, p. 
275), among others, warn against using NPV distributions for making investment decisions, as such 
distributions are difficult to interpret and do not correctly reflect the project’s risk when a risk-free 
discount rate is used to obtain them. Therefore, in our model, the project valuation is still based on 
NPV calculations using expected cash flows and a risk-adjusted discount rate, and simulation is 
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merely used as an advanced sensitivity analysis tool.  Its purpose is to visualize the risk sharing 
between Phytopharm and the licensee according to the proposed contract, and to enhance 
understanding of the impact of the contractual terms on the risk borne by the two parties.  It displays 
the typical structure of an R&D project, with a significant chance of a loss, and a highly uncertain 
value on the market. The cumulative distribution shows the same pattern, but allows a better 
comparison of the distributions.  Whereas Phytopharm will never incur losses due to the milestone 
payments, if we ignore the sunk costs of earlier investments, it does not have a large upside potential 
either, as opposed to the licensee, which benefits from a large upside potential at the expense of the 
possibility of losses. 
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Figure 11. A histogram shows the range and likelihood of possible NPV values for the project and for 
both parties, according to the proposed contract terms. 
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Figure 12. A cumulative probability distribution of the NPV shows the likelihood of obtaining a 
certain NPV for the project and for both parties. 
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Negotiations Model 
Since the model was primarily designed to be used during licensing negotiations, it was important for 
Phytopharm to have information on potential trade-offs that could be made, in case some of the terms 
of the proposed agreement would not be satisfactory for the licensee.  If, for instance, the licensee 
deems that the proposed milestone payments are too high, these can be lowered without affecting 
Phytopharm’s NPV by increasing the royalties appropriately. 
In the model, we provide information on how an increase or decrease in milestones or the royalty 
percentage would affect Phytopharm’s NPV.  This information is shown in Figure 13 for the DCO 
product, where the top table contains the milestone and royalties deltas, and the bottom table is a so-
called “compensation table”, showing by how much one payment has to increase to compensate for 
another payment’s reduction in order to keep the NPV constant. 
 
Figure 13. The top section shows the impact of a change in the contract terms on Phytopharm’s 
NPV. The bottom section shows how a decrease in royalties or milestone payments can be 
compensated by an equivalent increase in milestone payments or royalties, respectively. 
The model also includes an analysis based on the concept of the positive bargaining zone 
(Bazerman, 2001). In a negotiation process, each party typically has a reservation point, namely their 
opportunity cost or the best alternative to a negotiated agreement (BATNA).  In our model, each party 
can specify a minimum value for the NPV of their part of any proposed contract.  The reservation 
point results in a limit to what each party can ask in order for the deal to go through. Our model 
includes the possibility to check the bounds, given the licensee’s reservation point, on the milestone 
payments given a certain royalties percentage, or, alternatively, on the royalties, given a milestone 
payment scheme.  This is shown in Figure 14.  For instance, the right-hand side of the table shows the 
reservation points of both parties, namely 20% and 50% of the project’s NPV, and below, given the 
specified milestones of a total value of £3,374,000, the range on the royalty percentage that would 
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yield NPV values for both parties at or above their reservation point.  In this case, the royalty 
percentage could be anywhere between 4.57% and 13.94%.  The left side of the table yields similar 
results, but in terms of milestones payment ranges for specified royalties. 
 
Figure 14. This table displays the “bargaining zone” for royalties and milestone payments.  For a 
specified royalty percentage or milestone payment, the table shows the possible range on milestones 
or royalties satisfying the reservation points. 
 
Model Use 
Internal Model Use 
Given Phytopharm’s strategic focus on licensing, this project was of major importance to the 
company.  Therefore it had top management’s complete support and the resulting model was widely 
circulated amongst its employees.  This resulted in feedback from different perspectives, ensuring the 
model’s comprehensiveness.  The main user of the model was the CFO, Dr Wang Chong.  The other 
executive directors also requested to be instructed on the working of the model.  The development of 
the model thus became very interactive, with important input from end-users.  Some features have 
been added explicitly at their request, such as flexibility in the number of phases or a suggested 
milestone based on the project’s risk resolution profile.  We have also included IRR calculations and 
Payback Period information at Phytopharm’s request.  Though we are fully aware of the 
disadvantages of these measures in decision making, Phytopharm felt that the negotiation partner 
would like to know those values as they are commonly used in practice.  The wide circulation of the 
model also assisted the transparency and robustness of the model.  Also, some features in the model 
were designed for internal use only and could be hidden from the negotiation partner if required, such 
as information on Phytopharm’s obligations to third parties or the tornado diagram, which highlights 
the uncertainties in the model that have the highest impact on the projects’ NPV estimate. 
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External Model Use 
Phytopharm used the model during its licensing negotiations for the DCO product between June and 
December 2004.  In December 2004, the product was licensed to Unilever, a multinational food 
company (see press release in Figure 15).  We had initially offered our assistance in presenting and 
running the model at the negotiation meetings with short-listed potential collaboration partners.  
However, using an ‘interpreter’ makes negotiations more difficult and Phytopharm felt confident in 
using and defending the model during the negotiations.  From Phytopharm’s comments, we gathered 
that the negotiation partners were surprised by the sophistication of the model. 
Figure 15. On 15 December 2004, a press release was issued to announce the licensing deal. 
The main advantage of the model, according to Phytopharm, was that it enabled the negotiations 
team to make a robust case for providing credible estimates of the product’s value.  Valuing a product 
in early development for licensing negotiations can be a major challenge, as the NPV can be 
discounted close to zero using a standard DCF/NPV model when the product’s launch is many years 
Phytopharm and Unilever enter into a License and Joint Development 
Agreement includes provisions for substantial milestone payments and royalties 
Phytopharm plc (LSE: PYM; NASDAQ: PHYOF) announced today that it has granted
an exclusive global license to its Hoodia gordonii extract to Unilever plc, the global
consumer products company and owner of a number of the world's leading brands. 
As part of the agreement, Unilever will commit to initial payments totaling
approximately £6.5 million ($12.5 million) out of a potential total of £21 million ($40
million) in payments to Phytopharm. In addition Phytopharm will receive an
undisclosed royalty on sales of all products containing the extract. 
The extract of Hoodia gordonii, a South African plant, was licensed exclusively by
Phytopharm from the South African Council for Scientific and Industrial Research
(CSIR) in 1997. Phytopharm has been actively developing the extract for incorporation
into weight loss products. 
Unilever and Phytopharm will collaborate on a five-stage research and development
program of safety and efficacy studies with a view to bringing new products to market.
Unilever will also manage a separate agronomy program and will support the
international patent program for the products. 
Obesity has reached epidemic proportions globally, with more than 1 billion adults
overweight - at least 300 million of them clinically obese - and is a major contributor to
the global burden of chronic disease and disability (Source: World Health
Organization). 
Commenting on today's announcement, Dr. Richard Dixey, Chief Executive Officer of
Phytopharm, said: "We are delighted to enter into this agreement with the global leader
in weight management products. Our partnership with Unilever supports the
development of this product with milestones and a fully funded program and we look
forward to generating royalty income from our partner's globally recognized brands." 
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away.  Typically during such negotiations, the different parties disagree on crucial parameters that 
influence a product’s value, such as the sales forecasts, development costs, margins, likelihood of 
success, etc., as well as the appropriate discount rate to be used.  Our model allowed the negotiations 
teams to visualize the effect of these different assumptions, and to determine which of these factors 
had a significant impact on value, and which did not.  This allowed a more focused discussion on the 
important issues.  In particular, the model was helpful to discuss and finally determine the PTS and 
the sales estimates.  The model was also useful for visualizing the structure of the project, including 
the different clinical trials and review procedures.  Although pharmaceutical companies are used to 
operating in this environment, food companies typically deal with more straightforward product 
development processes, and are sometimes apprehensive to take on risky projects like the DCO 
project.  The model provided a clear overview of all the phases and risks involved, and therefore 
enabled Phytopharm to propose a deal that would otherwise be alien to most players in the food and 
consumer goods industries.  The visualization provided by the model, for instance in the form of 
probability distributions, was a useful tool to show the risk sharing element in the contract.  The 
graphs clearly showed different risk profiles for the different partners, with higher risks compensated 
with higher potential upsides.  This allowed Phytopharm to convince their potential licensing partners 
of the merit of the product.  Currently, Phytopharm is planning to deploy the model for its entire 
project portfolio. 
 
Conclusions 
In this paper, we describe an R&D project valuation model developed for Phytopharm plc, a UK 
biotechnology company, to be used during licensing negotiations.  Using Decision Analysis and 
Monte Carlo Simulation, we determine the Net Present Value of an R&D project, and determine the 
magnitude of the risks involved, both technical and commercial.  The model is currently being used 
by Phytopharm to develop contract proposals consisting of milestone payments and royalties on sales, 
based on an agreed-upon equitable split of the project value between the two parties.  The model also 
generates useful information in the form of break-even analyses, trade-offs and bargaining zones.  
Between June and December 2004, Phytopharm used the model during its licensing negotiations for a 
novel product for the dietary control of obesity, which resulted in the product being licensed to 
Unilever, a multinational food and consumer goods company. 
Phytopharm is currently planning to deploy the model for its entire project portfolio.  Even though 
Phytopharm only develops products based on plant extracts with strong anecdotal evidence of clinical 
benefit, hence theoretically improving the probability of technical success of its projects, it still carries 
substantial technical risk. Whereas the major pharmaceutical companies can diversify the technical 
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risk of their portfolio through the number of projects involved, smaller pharmaceutical players bear a 
substantial amount of risk due to their comparatively small portfolios; Phytopharm’s portfolio 
contains approximately 10 projects. For smaller companies, losing a project, failing to license a 
project or getting a bad deal on a project might be life threatening, emphasizing the importance and 
the need for quality project valuation tools.  
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